Production and characterization of a monoclonal antibody against human calcitonin gene-related peptide (CGRP) and its immunohistochemical application to salivary glands

1994 ◽  
Vol 26 (4) ◽  
pp. 317-326 ◽  
Author(s):  
Ewa Szabat ◽  
Antero Salo ◽  
Ismo Virtanen ◽  
Hannu Uusitalo ◽  
Seppo Soinila
Author(s):  
Eric Moore ◽  
Mark E. Fraley ◽  
Ian M. Bell ◽  
Christopher S. Burgey ◽  
Rebecca B. White ◽  
...  

2004 ◽  
Vol 65 (1) ◽  
pp. 207-213 ◽  
Author(s):  
Kenji Kuwasako ◽  
Yuan-Ning Cao ◽  
Yasuko Nagoshi ◽  
Toshihiro Tsuruda ◽  
Kazuo Kitamura ◽  
...  

Nature ◽  
1984 ◽  
Vol 308 (5961) ◽  
pp. 746-748 ◽  
Author(s):  
Howard R. Morris ◽  
Maria Panico ◽  
Tony Etienne ◽  
John Tippins ◽  
Samia I. Girgis ◽  
...  

2020 ◽  
Vol 374 (1) ◽  
pp. 93-103
Author(s):  
Leon F. Garcia-Martinez ◽  
Carol J. Raport ◽  
Ethan W. Ojala ◽  
Benjamin Dutzar ◽  
Katie Anderson ◽  
...  

2020 ◽  
Author(s):  
Lindsay M Frerichs ◽  
Deborah I Friedman

Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.


Sign in / Sign up

Export Citation Format

Share Document